A case report published on 26 August describes a man in his mid-30s with long-standing type 1 diabetes who was admitted to hospital with severe vomiting, diarrhoea, high blood sugar, ketones and acute kidney injury, shortly after self-administering a product he had bought online marketed as retatrutide. His partner took the same preparation and also … Read more
Eli Lilly reported on 23 July 2026 that retatrutide, an investigational triple hormone receptor agonist, met its primary endpoint in two further Phase 3 trials. Participants with obesity and type 2 diabetes lost up to an average of 20.8% of body weight over 80 weeks; those with severe obesity and established cardiovascular disease lost up … Read more
The FDA’s Center for Drug Evaluation and Research issued warning letters dated 24 August 2026 to five online peptide sellers — TXP Innovations LLC dba Tex Peptides, Royal Peptides LLC, NuScience Peptides LLC, Peptide Partners LLC and Peak Performance Peptides — posted 1 September 2026. Each followed a July 2026 review of the firm’s website … Read more
Eli Lilly filed six lawsuits on 12 August 2026 against US entities selling black-market retatrutide, an investigational molecule in Phase 3 trials that no regulator has approved for human use. The defendants are Aesthetic Envy Cosmetic Centers, Astra Peptides, Legendary Peptides, Striker Pharmacy, Texas Peptides and Lone Star Peptide: compounding pharmacies, medical spas and online … Read more